{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:12:24Z","timestamp":1775470344872,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.semarthrit.2018.03.016","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T17:13:08Z","timestamp":1522257188000},"page":"513-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Medications received by patients with juvenile dermatomyositis"],"prefix":"10.1016","volume":"48","author":[{"given":"Takayuki","family":"Kishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nastaran","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1689","authenticated-orcid":false,"given":"Adam M.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulnara","family":"Mamyrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira N.","family":"Targoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Warren-Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa G.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.03.016_bib1","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","article-title":"Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood","volume":"371","author":"Feldman","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.rdc.2013.06.001","article-title":"Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies","volume":"39","author":"Rider","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib5","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-3476(83)80706-9","article-title":"Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification","volume":"103","author":"Bowyer","year":"1983","journal-title":"J Pediatr"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib6","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/art.21378","article-title":"The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids","volume":"52","author":"Ramanan","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.1780300312","article-title":"Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis","volume":"30","author":"Laxer","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0002-9343(91)90010-U","article-title":"Treatment of dermatomyositis with intravenous gammaglobulin","volume":"91","author":"Lang","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib9","first-page":"2498","article-title":"Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety","volume":"27","author":"Al Mayouf","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0889-857X(05)70350-1","article-title":"Classification and treatment of the juvenile idiopathic inflammatory myopathies","volume":"23","author":"Rider","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrrheum.2011.139","article-title":"Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis","volume":"7","author":"Robinson","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1759720X11424460","article-title":"Juvenile dermatomyositis: new insights and new treatment strategies","volume":"4","author":"Martin","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib14","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3899\/jrheum.090953","article-title":"Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey","volume":"37","author":"Stringer","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib15","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/art.30475","article-title":"Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study","volume":"63","author":"Hasija","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two pars)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib21","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kD protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.39466","article-title":"Brief Report: association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis","volume":"68","author":"Habers","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/acr.22212","article-title":"Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies","volume":"66","author":"Huber","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","article-title":"Race, income, and disease outcomes in juvenile dermatomyositis","volume":"184","author":"Phillippi","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib26","first-page":"117","article-title":"Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis","volume":"29","author":"Guseinova","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib28","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","article-title":"Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset","volume":"48","author":"Sanner","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/adc.72.1.25","article-title":"Intravenous immunogloblin in juvenile dermatomyositis\u2014four year review of nine cases","volume":"72","author":"Sansome","year":"1995","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib30","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1136\/ard.2011.153718","article-title":"Efficacy of intravenous Ig therapy in juvenile dermatomyositis","volume":"70","author":"Lam","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib31","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib32","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib33","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.23341","article-title":"Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis","volume":"59","author":"Rouster-Stevens","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40257-013-0028-6","article-title":"Cutaneous dermatomyositis: an updated review of treatment options and internal associations","volume":"14","author":"Femia","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1546-0096-10-34","article-title":"Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center\u2019s experience","volume":"10","author":"Patwardhan","year":"2012","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.03.016_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217307539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217307539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T11:54:58Z","timestamp":1719921298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217307539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0049017217307539"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.016","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medications received by patients with juvenile dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}